Source comparison
CJC-1295 Research: Peptide Comparison
CJC-1295 (with DAC) 6–8 days Weekly GHRH receptor agonist with albumin binding Sustained pulsatile elevation over 7+ days Long-term body composition, metabolic health studies Modified GRF(1-29) ~30 minutes 2–3x daily GHRH receptor agonist without albumin bindi
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- 6–8 days
- Weekly
- GHRH receptor agonist with albumin binding
- Sustained pulsatile elevation over 7+ days
- Long-term body composition, metabolic health studies
- Modified GRF(1-29)
- ~30 minutes
- 2–3x daily
- GHRH receptor agonist without albumin binding
- Acute GH pulse 15–45 min post-dose
- Acute GH dynamics, combination protocols with GHRPs
- GHRP-2
- ~20 minutes
- Ghrelin receptor agonist (GHS-R1a)
- Sharp GH pulse, synergistic with GHRH analogues
- Pulse amplitude studies, combination with CJC-1295 or Mod GRF
- Native GHRH(1-29)
- <7 minutes
- Continuous infusion required
- GHRH receptor agonist
- Physiological pulsatile pattern (if infused correctly)
- Basic receptor pharmacology, not practical for long-term studies
- The bottom line: if a research protocol requires dosing intervals longer than 48 hours, CJC-1295 with DAC is the only viable GHRH analogue. Modified GRF(1-29) offers better control for acute studies but introduces adherence complexity in human trials requiring twice-daily administration over weeks or months.